Synaptogenix Inc (SNPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synaptogenix Inc (SNPX) has a cash flow conversion efficiency ratio of -0.042x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-749.07K) by net assets ($17.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Synaptogenix Inc (SNPX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Synaptogenix Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Synaptogenix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synaptogenix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
-0.270x |
|
Jet.AI Inc.
NASDAQ:JTAI
|
0.031x |
|
EA Holdings Bhd
KLSE:0154
|
-0.070x |
|
Eros International Media Limited
NSE:EROSMEDIA
|
-0.061x |
|
The Agency Group Australia Ltd
AU:AU1
|
1.111x |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
N/A |
|
Olive Resource Capital Inc
V:OC
|
0.071x |
|
AB Effectenbeteiligungen AG
STU:JPH
|
N/A |
Annual Cash Flow Conversion Efficiency for Synaptogenix Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Synaptogenix Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see SNPX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.78 Million | $-4.88 Million | -0.721x | -256.43% |
| 2023-12-31 | $25.58 Million | $-5.17 Million | -0.202x | +36.13% |
| 2022-12-31 | $35.41 Million | $-11.21 Million | -0.317x | -21.86% |
| 2021-12-31 | $33.53 Million | $-8.71 Million | -0.260x | +83.52% |
| 2020-12-31 | $5.14 Million | $-8.10 Million | -1.577x | -131.06% |
| 2019-12-31 | $17.42 Million | $-11.89 Million | -0.682x | -135.14% |
| 2018-12-31 | $26.52 Million | $-7.70 Million | -0.290x | -- |
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more